Pharmaceutical Excipients Market

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates [Sugar (Dextrose)], Inorganic Chemicals), Functionality (Fillers, Diluents, Coating, Disintegrants), Formulation (Tablet, Capsule, Topical, Parenteral) - Global Forecast to 2026

Report Code: PH 3047 Mar, 2021, by marketsandmarkets.com

[303 Pages Report] The pharmaceutical excipients  market is projected to reach USD 10.6 billion by 2026 from USD 7.9 billion in 2021, at a CAGR of 5.8% during the forecast period. Growth in this market is majorly driven by the growing pharmaceutical industry coupled with the increasing R&D activities taking place in this field. Also, the growing generics market, rapidly growing biopharmaceuticals sector and the rising adoption of orphan drugs are supporting the growth of the market.

On the other hand, the increasing regulatory stringency regarding the approval of drugs and excipients is expected to restrain the growth of this market during the forecast period. The quality of pharmaceutical excipients throughout their life cycle plays a crucial role in patient safety. The effects of low-quality excipients, such as reduced API bioavailability, have further increased the importance of controlling various aspects of the excipient life cycle, including designing, manufacturing, and transportation. The importance of excipient quality is recognized by the global pharmaceutical industry and various regulatory agencies worldwide. In this regard, various governments are developing legislation related to sourcing and manufacturing excipients for the pharmaceutical industry that has restrained the industry growth to some extent

Pharmaceutical Excipients Market

To know about the assumptions considered for the study, download the pdf brochure

COVID-19 Impact on Global Pharmaceutical Excipients Market

The COVID-19 pandemic had a significant impact on the pharma industry. Lockdowns imposed in the wake of the outbreak disrupted the supply of raw materials from manufacturing hubs such as India and China. This slowed drug development and manufacturing, with severe impacts on companies that relied heavily on outsourcing. The entire pharmaceutical ecosystem was disrupted initially. Moreover, regulatory authorities also had to reframe and construct new laws to ensure maximum patient safety after drug consumption. The end of the lockdowns saw the pharma industry gaining momentum, especially given the demand for drugs such as hydroxychloroquine and Remdesivir, which showed positive results against COVID-19. The increasing demand for these drugs drove revenue growth for some companies. The above mentioned factors  suggest that the Covid-19 impact on the pharmaceutical excipients market is negligible as it is the starting material in manufacturing of pharmaceutical drugs.

Pharmaceutical Excipients  Market Dynamics

Driver:  Increasing uptake of biopharmaceuticals

Biopharmaceuticals are gradually becoming popular in the healthcare industry due to their similarity to natural biological compounds found in the human body; thus, they offer high efficacy and fewer side-effects. They form one of the fastest-growing segments of the pharmaceutical industry. Novel concepts like cell therapy (for cancer treatment) and gene therapy (offering regenerative medicine) are steadily being refined. This presents an attractive opportunity for further growth in this sector.

The efficacy and safety associated with biopharmaceutical products, combined with their ability to address previously untreatable conditions, allows pharmaceutical companies to command high prices for innovative drugs, thus contributing significantly to their overall revenue. The majority of the blockbuster drugs currently available in the market are biopharmaceuticals, among the top 15 biopharmaceutical products. Hence, major pharmaceutical companies across the globe are increasingly shifting their R&D focus to large-molecule products.

Restraint: Cost and time-intensive drug development process

According to the California Biomedical Research Association (CBRA), it takes an average of 12 years for a drug to travel from the research lab to the patient, including 1–6 years for toxicology studies alone. Also, only 5 in 5,000 drugs that begin preclinical testing ever make it to human testing. Of these, only one is approved for human usage. Moreover, late-stage failures in the drug development process increase R&D costs and impact the profit margins of pharmaceutical companies. The intensifying regulations on the quality and safety of the excipients and drugs result in the need to upgrade current manufacturing and quality assurance practices, which adds to the overall manufacturing cost. Thus, although excipient and drug production have seen significant advances in recent years, the requirement of high capital investments is expected to hamper market growth during the forecast period.

Opportunity: Shifting focus of pharmaceutical manufacturing to emerging countries

The traditionally lucrative pharmaceuticals market is becoming challenging from a growth perspective due to the diminishing drug pipeline, government-induced pressures on healthcare cost, and the increasing regulations on innovative products. This is encouraging pharmaceutical manufacturers to move their manufacturing bases closer to high-growth emerging markets. Through this, manufacturers can take advantage of low-cost manufacturing and financial benefits in terms of attractive tax rates and lenient regulatory guidelines for manufacturing.  Many major excipient manufacturers are either planning capacity expansions of their existing plants in emerging countries or setting up new manufacturing plants in emerging markets such as China and India.

Challenge:  Safety and quality concerns

With the current changes in government policies all over the world, upcoming trade policies could prove to be a challenge for the pharmaceutical industry, and in turn, the excipients industry. Trade between the developing countries who are considered to be pharmerging countries such as China, India, and Brazil and developed countries like the US and European countries, who are top markets in the industry, could be severely affected. BREXIT is another pressing issue in this market. The possibility of fallout originating from Britain’s exit from the EU has led companies to consider shifting—or shift—their manufacturing from the UK to Germany, France, and other European countries. Although the effects of BREXIT on the pharmaceutical industry are still unclear, companies like Novartis, Astra Zeneca, and Roche have already shifted manufacturing sites in order to reduce any further risks.

The organic chemicals  segment is expected to grow at the highest CAGR during the forecast period

Based on product, the pharmaceutical excipients market is segmented into three major categories— organic chemicals, inorganic chemicals, and other chemicals. In 2020, the organic chemicals segment accounted for the largest market share. This segment is also projected to register the highest CAGR during the forecast period. In 2020, the organic chemicals segment accounted for the largest share of the pharmaceutical excipients market. The large share of this segment can be attributed to the use of these chemicals in a majority of pharmaceutical formulations.

The fillers & dilluents segment is expected to account for the largest share of the pharmaceutical excipients market

Based on functionality, pharmaceutical excipients are categorized into fillers & diluents, binders, suspending & viscosity agents, flavoring agents & sweeteners, coating agents, colorants, disintegrants, lubricants & glidants, preservatives, emulsifying agents, and other functionalities. By functionality, fillers & diluents held the largest share in 2020. The demand for fillers and diluents is high as they are utilized in manufacturing tablets and capsules.

The oral formulations  segment is expected to grow at the highest rate during the forecast period

Based on the formulation, the pharmaceutical excipients market is segmented into oral, topical, parenteral, and other formulations. Oral formulations dominate this market due to their wide usage and efficacy against many ailments. Healthcare professionals recommended antiviral drugs as the primary line of defense against COVID-19. Due to their effectiveness in resolving pneumonia and respiratory ailments caused by the virus, these drugs were prescribed in large numbers. Since they are produced in tablet form for oral consumption, the oral formulations market has received a significant boost.

Europe is expected to account for the largest share of the pharmaceutical excipeints market in 2020

In 2020, Europe accounted for the largest share of the pharmaceutical excipients  market, followed by North America, the Asia Pacific, Latin America, and the Middle East & Africa. Many European countries are focusing their attention on the generics market due to the expiration of blockbuster drug patents in the coming years. As a result, the European region is expected to witness major growth in its generics market during the forecast period, which will propel the demand for pharmaceutical excipients. Increasing government initiatives in countries such as Germany, Italy, and Spain for reducing drug prices are expected to drive the market for generic drugs in these countries. The abovementioned factors, alongside increasing investments for the development of biologics and advanced dosage forms, will increase the demand for novel excipients and thereby aid the growth of the pharmaceutical excipients market in Europe.

Pharmaceutical Excipients Market  by Region

Key Market Players

The prominent players in this market are Ashland Global Holdings (US), BASF SE (Germany), DuPont (US), Roquette Feres (France), Evonik Industries AG (Germany), Associated British Foods (UK), Archer Daniels Midland Company (US), Lubrizol Corporation (US), and Croda International (UK). Other players in this market are Innophous Holdings (US), Kerry Group (Ireland), WACKER Chemie AG (Germany), Colorcon (US), DFE Pharma (Germany), JRS Pharma (Germany), and Air Liquide (France).

Scope of the report

Report Metric

Details

Market size available for years

2019-2026

Base year considered

2020

Forecast period

2021-2026

Forecast units

Value (USD Billion)

Segments covered

Product, Functionality and Formulations

Geographies covered

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa

Companies covered

Ashland Global Holdings (US), BASF SE (Germany), DuPont (US), Roquette Feres (France), Evonik Industries AG (Germany), Associated British Foods (UK), Archer Daniels Midland Company (US), Lubrizol Corporation (US), and Croda International (UK). Other players in this market are Innophous Holdings (US), Kerry Group (Ireland), WACKER Chemie AG (Germany), Colorcon (US), DFE Pharma (Germany), JRS Pharma (Germany), and Air Liquide (France).

The study categorizes the Pharmaceutical excipients Market based on polymer type, functionality, type, end user, and regional and global level.

Global Pharmaceutical Excipients Market, by Product

  • Organic Chemicals
  • Inorganic Chemicals
  • Others

Global Pharmaceutical Excipients Market, by Functionality

  • Fillers and Diluents
  • Suspending and Viscosity Agents
  • Coating Agents
  • Binders
  • Flavoring Agents and Sweeteners
  • Disintegrants
  • Colorants
  • Lubricants and Glidants
  • Preservatives
  • Emulsifying Agents
  • Other Functionalities

Global Pharmaceutical Excipients Market, by Formulations

  • Oral Formulations
  • Topical Formulations
  • Parenteral Formulations
  • Other Formulations

Global Pharmaceutical excipients Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Switzerland
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of APAC
  • Latin America
  • Middle East & Africa

Recent Developments

  • In 2020, Colorcon launched the Acryl-EZE II film coating line which extends the pH range covered by its enteric coatings.
  • In 2020, Evonik launched the EUDRATEC Fasteric releases, an advanced oral drug delivery technology that provides enteric protection followed by rapid, homogeneous release for effective targeting of the upper small intestine.
  • In 2018, Roquette (France) signed an agreement with Thermo Fisher. Roquette signed an agreement with ThermoFisher Scientific (US), which gives Thermo the right to distribute Roquette’s products in the US and Canada. This will provide further market access to Roquette.
  • In 2019, Ashland announced the launch of Aquarius Nutra TF, which provides titanium oxide-based coating to tablets in the European market.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 35)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           FIGURE 1 PHARMACEUTICAL EXCIPIENTS MARKET
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY

2 RESEARCH METHODOLOGY (Page No. - 39)
    2.1 RESEARCH APPROACH
           FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY RESEARCH
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY RESEARCH
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Breakdown of primaries
           FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
           FIGURE 4 BOTTOM-UP APPROACH
           FIGURE 5 TOP-DOWN APPROACH
           FIGURE 6 REVENUE SHARE ANALYSIS
           FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF THE PHARMACEUTICAL EXCIPIENTS MARKET
           FIGURE 8 CAGR PROJECTIONS FROM THE ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES OF THE PHARMACEUTICAL EXCIPIENTS INDUSTRY (2020-2026)
    2.3 DATA TRIANGULATION APPROACH
           FIGURE 9 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ESTIMATION
    2.5 ASSUMPTIONS FOR THE STUDY
    2.3 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
           FIGURE 10 CRITERIA IMPACTING THE GLOBAL ECONOMY
           FIGURE 11 SCENARIOS FOR THE RECOVERY OF THE GLOBAL ECONOMY

3 EXECUTIVE SUMMARY (Page No. - 51)
           FIGURE 12 PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
           FIGURE 13 ORGANIC CHEMICALS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
           FIGURE 14 PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2021 VS. 2026 (USD MILLION)
           FIGURE 15 PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2021 VS. 2026 (USD MILLION)
           FIGURE 16 GEOGRAPHICAL SNAPSHOT OF THE PHARMACEUTICAL EXCIPIENTS MARKET

4 PREMIUM INSIGHTS (Page No. - 55)
    4.1 PHARMACEUTICAL EXCIPIENTS: MARKET OVERVIEW
           FIGURE 17 GROWING PHARMACEUTICALS INDUSTRY COUPLED WITH ADVANCEMENTS IN FUNCTIONAL EXCIPIENTS ARE KEY FACTORS DRIVING MARKET GROWTH
    4.2 PHARMACEUTICAL EXCIPIENTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 18 ASIA PACIFIC COUNTRIES TO SHOW THE HIGHEST GROWTH DURING THE FORECAST PERIOD
    4.3 REGIONAL MIX: PHARMACEUTICAL EXCIPIENTS MARKET (2021–2026)
           FIGURE 19 EUROPE TO HOLD THE LARGEST SHARE OF THE MARKET DURING THE FORECAST PERIOD (2021–2026)
    4.4 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BY FORMULATION AND COUNTRY (2020)
           FIGURE 20 ORAL FORMULATIONS ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2020

5 MARKET OVERVIEW (Page No. - 59)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 21 PHARMACEUTICAL EXCIPIENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
           5.2.1 MARKET DRIVERS
                    5.2.1.1 Growth of the pharmaceuticals market backed by functional excipients
           FIGURE 22 GLOBAL PHARMACEUTICAL DRUG SALES (2008–2022)
                    5.2.1.2 Surge in the generics market
           TABLE 1 DRUG PATENT EXPIRY, BY YEAR
                    5.2.1.3 Increasing uptake of biopharmaceuticals
                    5.2.1.4 Rising adoption of orphan drugs
           FIGURE 23 INCREASING PENETRATION OF ORPHAN DRUGS (2010–2024)
           FIGURE 24 RISING NUMBER OF ORPHAN INDICATIONS APPROVED IN THE US
           TABLE 2 KEY MARKET DRIVERS: IMPACT ANALYSIS
           5.2.2 MARKET RESTRAINTS
                    5.2.2.1 Cost and time-intensive drug development process
                    5.2.2.2 Increasing regulatory stringency
           TABLE 3 KEY MARKET RESTRAINTS: IMPACT ANALYSIS
           5.2.3 MARKET OPPORTUNITIES
                    5.2.3.1 Multifunctional excipients
           TABLE 4 MULTIFUNCTIONAL EXCIPIENTS
                    5.2.3.2 Shifting focus of pharmaceutical manufacturing to emerging countries
                    5.2.3.3 Growth in the biosimilars market
           FIGURE 25 TOTAL NUMBER OF NEW MOLECULAR ENTITY (NME) & NEW BIOLOGIC LICENSE APPLICATION (BLA) FILINGS AND APPROVALS IN THE US, 2006–2018
           TABLE 5 CLINICAL STUDIES FOR BIOLOGICS & BIOSIMILARS (2017)
           TABLE 6 KEY MARKET OPPORTUNITIES: IMPACT ANALYSIS
           5.2.4 MARKET CHALLENGES
                    5.2.4.1 Safety and quality concerns
                    5.2.4.2 Changing trade policies
           TABLE 7 KEY MARKET CHALLENGES: IMPACT ANALYSIS
    5.3 COVID-19 IMPACT
           FIGURE 26 INCREASE IN REVENUE, BY QUARTER
           FIGURE 27 COVID-19 IMPACT ON SECTIONS OF THE PHARMACEUTICAL INDUSTRY

6 INDUSTRY INSIGHTS (Page No. - 72)
    6.1 INTRODUCTION
    6.2 INDUSTRY TRENDS
           FIGURE 28 INCREASING FOCUS ON CO-PROCESSED EXCIPIENTS AND USE OF NANOTECHNOLOGY ARE THE LEADING TRENDS IN THE INDUSTRY
           6.2.1 RISING DEMAND FOR CO-PROCESSED EXCIPIENTS
           TABLE 8 MARKETED CO-PROCESSED EXCIPIENTS
           6.2.2 IMPROVING EXCIPIENT CAPABILITIES USING NANOTECHNOLOGY
           6.2.3 INCREASING USE OF DIRECT COMPRESSION IN ORAL DOSAGE FORMULATIONS
           6.2.4 PHARMACEUTICAL EXCIPIENTS INFLUENCING THE COST OF PRODUCTION
    6.3 REGULATORY ANALYSIS
           6.3.1 NORTH AMERICA
                    6.3.1.1 US
                    6.3.1.2 Canada
           6.3.2 EUROPE
           6.3.3 ASIA PACIFIC
                    6.3.3.1 Japan
                    6.3.3.2 China
                    6.3.3.3 India
    6.4 PORTER’S ANALYSIS
           TABLE 9 PORTER’S FIVE FORCES ANALYSIS
           6.4.1 INTENSITY OF COMPETITIVE RIVALRY
           6.4.2 BARGAINING POWER OF SUPPLIERS
           6.4.3 BARGAINING POWER OF BUYERS
           6.4.4 THREAT OF SUBSTITUTES
           6.4.5 INTENSITY OF NEW ENTRANTS
    6.5 ECOSYSTEM ANALYSIS
    6.6 PATENT ANALYSIS
           FIGURE 29 PATENT ANALYSIS: NUMBER OF PUBLICATIONS FOR THE PHARMACEUTICAL INDUSTRY
           TABLE 10 PROMINENT PHARMACEUTICAL EXCIPIENT PATENTS
    6.7 TRADE DATA
    6.8 PRICING ANALYSIS
           6.8.1 US
           6.8.2 CHINA
           6.8.3 INDIA

7 PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT (Page No. - 88)
    7.1 INTRODUCTION
           TABLE 11 PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 12 PHARMACEUTICAL EXCIPIENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.2 ORGANIC CHEMICALS
           TABLE 13 ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 14 ORGANIC CHEMICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.2.1 OLEOCHEMICALS
           TABLE 15 OLEOCHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 16 OLEOCHEMICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.1.1 Fatty alcohols
                               7.2.1.1.1 Fatty alcohols are widely used as nonionic surfactants due to their amphipathic nature—a major driver for market growth
           TABLE 17 FATTY ALCOHOLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.1.2 Mineral stearates
                               7.2.1.2.1 Wide use of magnesium stearates as excipients in nutraceutical and pharmaceutical formulations to drive market growth
           TABLE 18 MINERAL STEARATES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.1.3 Glycerin
                               7.2.1.3.1 Extensive applications of glycerin to drive market growth
           TABLE 19 GLYCERIN MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.1.4 Other oleochemicals
           TABLE 20 OTHER OLEOCHEMICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.2.2 CARBOHYDRATES
           TABLE 21 CARBOHYDRATES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 22 CARBOHYDRATES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.2.1 Sugars
           TABLE 23 SUGARS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 24 SUGARS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                               7.2.2.1.1 Actual sugars
           TABLE 25 ACTUAL SUGARS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 26 ACTUAL SUGARS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                             7.2.2.1.1.1 Lactose
                                                             7.2.2.1.1.1.1 Lactose is the most commonly used excipient in tablets and capsules
                                             7.2.2.1.1.2 Sucrose
                                                              7.2.2.1.1.2.1 Sucrose is extensively used in oral pharmaceutical formulations
                                             7.2.2.1.1.3 Dextrose (D-Glucose)
                                                              7.2.2.1.1.3.1 Dextrose has a wide range of applications in tablets and capsules
                               7.2.2.1.2 Sugar alcohols
           TABLE 27 SUGAR ALCOHOLS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 28 SUGAR ALCOHOLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                             7.2.2.1.2.1 Mannitol
                                                               7.2.2.1.2.1.1 Mannitol is widely used with moisture-sensitive active ingredients as it is non-hygroscopic in nature
                                             7.2.2.1.2.2 Sorbitol
                                                               7.2.2.1.2.2.1 Sorbitol is one of the most widely used compression diluents for pharmaceutical formulations
                                             7.2.2.1.2.3 Other sugar alcohols
                               7.2.2.1.3 Artificial sweeteners
                                             7.2.2.1.3.1 Aspartame is the most commonly used artificial sweetener
           TABLE 29 ARTIFICIAL SWEETENERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.2.2 Cellulose
           TABLE 30 CELLULOSE MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 31 CELLULOSE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                               7.2.2.2.1 Microcrystalline cellulose
                                             7.2.2.2.1.1 Microcrystalline cellulose is the most widely used excipient in the direct compression method for tablets
           TABLE 32 MICROCRYSTALLINE CELLULOSE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                               7.2.2.2.2 Cellulose ethers
                                             7.2.2.2.2.1 Cellulose ethers are effective even at a lower concentration
           TABLE 33 CELLULOSE ETHERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                               7.2.2.2.3 CMC and croscarmellose sodium
                                             7.2.2.2.3.1 Multiple advantages of CMC and croscarmellose sodium make them the most widely used suspending agents in injectable preparations
           TABLE 34 CMC & CROSCARMELLOSE SODIUM MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                               7.2.2.2.4 Cellulose esters
                                             7.2.2.2.4.1 Cellulose esters enable the delivery of drugs in cellular membranes and the intracellular matrix
           TABLE 35 CELLULOSE ESTERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.2.3 Starch
           TABLE 36 STARCH MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 37 STARCH MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                               7.2.2.3.1 Modified starch
                                             7.2.2.3.1.1 Modified starch is widely used in sustained-release tablets due to its cold-water swelling and gel barrier formation capabilities
           TABLE 38 MODIFIED STARCH MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                               7.2.2.3.2 Dried starch
                                             7.2.2.3.2.1 Dried starch is a strong binding and coating agent
           TABLE 39 DRIED STARCH MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                               7.2.2.3.3 Converted starch
                                             7.2.2.3.3.1 Converted starch is used as a molecular encapsulation agent and offers enhanced solubility and stability for drugs
           TABLE 40 CONVERTED STARCH MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.2.3 PETROCHEMICALS
           TABLE 41 PETROCHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 42 PETROCHEMICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.3.1 Glycols
           TABLE 43 GLYCOLS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 44 GLYCOLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                               7.2.3.1.1 Polyethylene glycol
                                             7.2.3.1.1.1 PEG is the excipient of choice in a large number of drug formulations due to its tunable properties and well-established safety profile
                               7.2.3.1.2 Propylene glycol
                                             7.2.3.1.2.1 In high amounts, propylene glycol has been reported to be toxic among the pediatric population
                    7.2.3.2 Povidones
                               7.2.3.2.1 Rising demand for fast-dissolving tablets is expected to propel the growth of this segment
           TABLE 45 POVIDONES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.3.3 Mineral hydrocarbons
           TABLE 46 MINERAL HYDROCARBONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 47 MINERAL HYDROCARBONS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                               7.2.3.3.1 Petrolatum
                                             7.2.3.3.1.1 Petrolatum is commonly used in topical formulations
                               7.2.3.3.2 Mineral waxes
                                             7.2.3.3.2.1 Mineral waxes are non-toxic and non-irritant in nature and are suitable for skin and eye preparations
                               7.2.3.3.3 Mineral oils
                                             7.2.3.3.3.1 White mineral oils are good emollients, lubricating agents, and solvents
                    7.2.3.4 Acrylic polymers
                               7.2.3.4.1 Wide use of acrylic polymers in controlled-release drug formulations to drive market growth
           TABLE 48 ACRYLIC POLYMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.3.5 Other petrochemicals
           TABLE 49 OTHER PETROCHEMICALS MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
           7.2.4 PROTEINS
                    7.2.4.1 Growing applications of proteins as carriers for microparticles and nanoparticles to drive market growth
           TABLE 50 PROTEINS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.2.5 OTHER ORGANIC CHEMICALS
           TABLE 51 OTHER ORGANIC CHEMICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.3 INORGANIC CHEMICALS
           TABLE 52 INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 53 INORGANIC CHEMICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.3.1 CALCIUM PHOSPHATE
                    7.3.1.1 Chemical purity and low incompatibility with drugs aid their high usage in the pharmaceutical industry
           TABLE 54 CALCIUM PHOSPHATE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.3.2 METAL OXIDES
                    7.3.2.1 Availability of silicon oxides in the hydrophobic, hydrophilic, and granulated forms to aid market growth
           TABLE 55 METAL OXIDES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.3.3 HALITES
                    7.3.3.1 Increased utilization of halites in vaccines and controlled-release formulations is driving their demand in the market
           TABLE 56 HALITES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.3.4 CALCIUM CARBONATE
                    7.3.4.1 Properties such as short disintegration time and excellent mechanical strength for oral dosage formulations to drive the market
           TABLE 57 CALCIUM CARBONATE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.3.5 CALCIUM SULFATE
                    7.3.5.1 Calcium sulfate is a cost-effective, quality-enhancing diluent for solid dosage forms
           TABLE 58 CALCIUM SULFATE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.3.6 OTHER INORGANIC CHEMICALS
           TABLE 59 OTHER INORGANIC CHEMICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.4 OTHER CHEMICALS
           TABLE 60 OTHER CHEMICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

8 PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY (Page No. - 129)
    8.1 INTRODUCTION
           TABLE 61 PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION)
    8.2 FILLERS & DILUENTS
           8.2.1 DILUENTS OFFER PROPERTIES SUCH AS IMPROVED COHESION, DIRECT COMPRESSION, AND FLOW TO THE FINAL DOSE IN TABLETS
           TABLE 62 PHARMACEUTICAL EXCIPIENTS MARKET FOR FILLERS & DILUENTS, BY COUNTRY, 2019–2026 (USD MILLION)
    8.3 SUSPENDING & VISCOSITY AGENTS
           8.3.1 SUSPENSIONS OFFER ADVANTAGES SUCH AS DRUG STABILITY AND TASTE MASKING
           TABLE 63 PHARMACEUTICAL EXCIPIENTS MARKET FOR SUSPENDING & VISCOSITY AGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
    8.4 COATING AGENTS
           8.4.1 INCREASING USE OF SUSTAINED-RELEASE FORMULATIONS IN THE PHARMA INDUSTRY TO DRIVE MARKET GROWTH
           TABLE 64 PHARMACEUTICAL EXCIPIENTS MARKET FOR COATING AGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
    8.5 BINDERS
           8.5.1 BINDERS PROVIDE THE PROPERTIES OF FLUIDITY AND COMPRESSIBILITY ESSENTIAL FOR TABLET MANUFACTURING
           TABLE 65 PHARMACEUTICAL EXCIPIENTS MARKET FOR BINDERS, BY COUNTRY, 2019–2026 (USD MILLION)
    8.6 FLAVORING AGENTS & SWEETENERS
           8.6.1 FLAVORING AGENTS ARE USED TO IMPROVE THE PALATABILITY OF DRUGS
           TABLE 66 PHARMACEUTICAL EXCIPIENTS MARKET FOR FLAVORING AGENTS & SWEETENERS, BY COUNTRY, 2019–2026 (USD MILLION)
    8.7 DISINTEGRANTS
           8.7.1 DISINTEGRANTS ARE FORMULATED TO CAUSE A RAPID BREAK-UP OF SOLIDS DOSAGE FORMS
           TABLE 67 PHARMACEUTICAL EXCIPIENTS MARKET FOR DISINTEGRANTS, BY COUNTRY, 2019–2026 (USD MILLION)
    8.8 COLORANTS
           8.8.1 COLORING AGENTS ARE USED IN HARD AND SOFT GELATIN CAPSULES, TABLETS, ORAL LIQUIDS, AND TOPICAL CREAMS
           TABLE 68 PHARMACEUTICAL EXCIPIENTS MARKET FOR COLORANTS, BY COUNTRY, 2019–2026 (USD MILLION)
    8.9 LUBRICANTS & GLIDANTS
           8.9.1 GLIDANTS IMPROVE THE FLOW PROPERTIES OF A FORMULATION BY REDUCING INTER-PARTICLE FRICTION AND COHESION
           TABLE 69 PHARMACEUTICAL EXCIPIENTS MARKET FOR LUBRICANTS & GLIDANTS, BY COUNTRY, 2019–2026 (USD MILLION)
    8.10 PRESERVATIVES
           8.10.1 BENZYL ALCOHOL IS A WIDELY USED PRESERVATIVE IN THE PHARMACEUTICAL AND NUTRACEUTICAL INDUSTRY
           TABLE 70 PHARMACEUTICAL EXCIPIENTS MARKET FOR PRESERVATIVES, BY COUNTRY, 2019–2026 (USD MILLION)
    8.11 EMULSIFYING AGENTS
           8.11.1 USE OF SOLUBILITY ENHANCEMENT EXCIPIENTS IN LIQUID DRUG FORMULATIONS HELPS INCREASE API BIOAVAILABILITY
           TABLE 71 PHARMACEUTICAL EXCIPIENTS MARKET FOR EMULSIFYING AGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
    8.12 OTHER FUNCTIONALITIES
           TABLE 72 OTHER FUNCTIONALITIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

9 PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION (Page No. - 143)
    9.1 INTRODUCTION
           TABLE 73 PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
    9.2 ORAL FORMULATIONS
           TABLE 74 PHARMACEUTICAL EXCIPIENTS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 75 PHARMACEUTICAL EXCIPIENTS MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
           9.2.1 TABLETS
                    9.2.1.1 Tablets are the most widely used dosage forms
           TABLE 76 TYPICAL COMPOSITION OF TABLETS
           TABLE 77 PHARMACEUTICAL EXCIPIENTS MARKET FOR TABLETS, BY COUNTRY, 2019–2026 (USD MILLION)
           9.2.2 CAPSULES
           TABLE 78 PHARMACEUTICAL EXCIPIENTS MARKET FOR CAPSULES, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 79 PHARMACEUTICAL EXCIPIENTS MARKET FOR CAPSULES, BY COUNTRY, 2019–2026 (USD MILLION)
                    9.2.2.1 Hard gelatin capsules
                               9.2.2.1.1 Ease of manufacturing and versatility are driving the growth of the hard gelatin capsules market
           TABLE 80 PHARMACEUTICAL EXCIPIENTS MARKET FOR HARD GELATIN CAPSULES, BY COUNTRY, 2019–2026 (USD MILLION)
                    9.2.2.2 Soft gelatin capsules
                               9.2.2.2.1 Stability concerns with highly water-soluble compounds and compounds susceptible to hydrolysis have restricted market growth
           TABLE 81 PHARMACEUTICAL EXCIPIENTS MARKET FOR SOFT GELATIN CAPSULES, BY COUNTRY, 2019–2026 (USD MILLION)
           9.2.3 LIQUID FORMULATIONS
                    9.2.3.1 Liquid formulations require no dissolution time and boast faster absorption from the stomach than tablets
           TABLE 82 PHARMACEUTICAL EXCIPIENTS MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
    9.3 TOPICAL FORMULATIONS
           9.3.1 ADVANTAGES OF TOPICAL DRUG DELIVERY ARE DRIVING THE DEMAND FOR EXCIPIENTS IN THIS SEGMENT
           TABLE 83 PHARMACEUTICAL EXCIPIENTS MARKET FOR TOPICAL FORMULATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
    9.4 PARENTERAL FORMULATIONS
           9.4.1 EMERGENCE OF NEW BIOLOGICAL MOLECULES TO INCREASE THE DEMAND FOR EXCIPIENTS
           TABLE 84 TYPICAL COMPOSITION OF PARENTERAL FORMULATIONS
           TABLE 85 EXCIPIENTS USED IN PARENTERAL FORMULATIONS
           TABLE 86 PHARMACEUTICAL EXCIPIENTS MARKET FOR PARENTERAL FORMULATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
    9.5 OTHER FORMULATIONS
           TABLE 87 PHARMACEUTICAL EXCIPIENTS MARKET FOR OTHER FORMULATIONS, BY COUNTRY, 2019–2026 (USD MILLION)

10 PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION (Page No. - 157)
     10.1 INTRODUCTION
           TABLE 88 PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2019–2026 (USD MILLION)
     10.2 EUROPE
             10.2.1 COVID-19 IMPACT ON THE EUROPEAN MARKET
           FIGURE 30 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET SNAPSHOT
           TABLE 89 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 90 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 91 EUROPE: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 92 EUROPE: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 93 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION)
           TABLE 94 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
             10.2.2 GERMANY
                        10.2.2.1 Germany accounted for the largest share of the European pharmaceutical excipients market in 2020
           TABLE 95 GERMANY: KEY MICROINDICATORS
           TABLE 96 GERMANY: PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 97 GERMANY: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 98 GERMANY: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 99 GERMANY: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION)
           TABLE 100 GERMANY: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
             10.2.3 FRANCE
                        10.2.3.1 Large geriatric population in the country to support market growth
           TABLE 101 FRANCE: KEY MICROINDICATORS
           TABLE 102 FRANCE: PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 103 FRANCE: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 104 FRANCE: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 105 FRANCE: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION)
           TABLE 106 FRANCE: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
             10.2.4 UK
                        10.2.4.1 Growing adoption of generics and the development of novel multi-functional, co-processed excipients to drive market growth
           TABLE 107 UK: KEY MICROINDICATORS
           TABLE 108 UK: PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 109 UK: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 110 UK: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 111 UK: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION)
           TABLE 112 UK: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
             10.2.5 SWITZERLAND
                        10.2.5.1 Large volume of pharmaceuticals produced in Switzerland is a key factor driving market growth
           TABLE 113 SWITZERLAND: KEY MICROINDICATORS
           TABLE 114 SWITZERLAND: PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 115 SWITZERLAND: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 116 SWITZERLAND: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 117 SWITZERLAND: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION)
           TABLE 118 SWITZERLAND: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
             10.2.6 ITALY
                        10.2.6.1 Budgetary constraints and restricted healthcare spending to impede the growth of the Italian market
           TABLE 119 ITALY: KEY MICROINDICATORS
           TABLE 120 ITALY: PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 121 ITALY: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 122 ITALY: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 123 ITALY: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION)
           TABLE 124 ITALY: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
             10.2.7 SPAIN
                        10.2.7.1 High consumption of biologics to support market growth
           TABLE 125 SPAIN: KEY MICROINDICATORS
           TABLE 126 SPAIN: PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 127 SPAIN: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 128 SPAIN: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 129 SPAIN: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION)
           TABLE 130 SPAIN: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
             10.2.8 REST OF EUROPE
           TABLE 131 ROE: PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 132 ROE: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 133 ROE: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 134 ROE: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION)
           TABLE 135 ROE: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
     10.3 NORTH AMERICA
             10.3.1 COVID-19 IMPACT ON THE NORTH AMERICAN MARKET
           FIGURE 31 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET SNAPSHOT
           TABLE 136 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 137 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 138 NORTH AMERICA: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 139 NORTH AMERICA: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 140 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION)
           TABLE 141 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
             10.3.2 US
                        10.3.2.1 The US dominates the North American market due to the increasing use of biologics and the increasing per capita pharmaceutical spending
           TABLE 142 US: KEY MICROINDICATORS
           TABLE 143 US: PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 144 US: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 145 US: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 146 US: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION)
           TABLE 147 US: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
             10.3.3 CANADA
                        10.3.3.1 Strong growth of the emerging markets and slowdown in new product approvals to hamper the market growth in Canada
           TABLE 148 CANADA: KEY MICROINDICATORS
           TABLE 149 CANADA: PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 150 CANADA: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 151 CANADA: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 152 CANADA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION)
           TABLE 153 CANADA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
     10.4 ASIA PACIFIC
             10.4.1 COVID-19 IMPACT ON THE APAC MARKET
           FIGURE 32 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET SNAPSHOT
           TABLE 154 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 155 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 156 ASIA PACIFIC: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 157 ASIA PACIFIC: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 158 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION)
           TABLE 159 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 The rapid growth of Japan’s geriatric population will greatly drive the demand for pharmaceuticals
           TABLE 160 JAPAN: KEY MICROINDICATORS
           TABLE 161 JAPAN: PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 162 JAPAN: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 163 JAPAN: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 164 JAPAN: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION)
           TABLE 165 JAPAN: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
             10.4.3 CHINA
                        10.4.3.1 Emphasis on generics and off-patent drugs to drive the market in China
           TABLE 166 CHINA: KEY MICROINDICATORS
           TABLE 167 CHINA: PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 168 CHINA: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 169 CHINA: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 170 CHINA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION)
           TABLE 171 CHINA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
             10.4.4 INDIA
                        10.4.4.1 India is a leading producer of generics
           TABLE 172 INDIA: KEY MICROINDICATORS
           TABLE 173 INDIA: PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 174 INDIA: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 175 INDIA: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 176 INDIA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION)
           TABLE 177 INDIA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION,2019–2026 (USD MILLION)
             10.4.5 SOUTH KOREA
                        10.4.5.1 Thriving generic drug market to support the growth of pharmaceutical excipients market in South Korea
           TABLE 178 SOUTH KOREA: PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 179 SOUTH KOREA: ORGANIC CHEMICALS MARKET, BY TYPE,2019–2026 (USD MILLION)
           TABLE 180 SOUTH KOREA: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 181 SOUTH KOREA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION)
           TABLE 182 SOUTH KOREA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
             10.4.6 REST OF ASIA PACIFIC
           TABLE 183 ROAPAC: PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 184 ROAPAC: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 185 ROAPAC: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 186 ROAPAC: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION)
           TABLE 187 ROAPAC: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
     10.5 LATIN AMERICA
             10.5.1 GROWING GERIATRIC POPULATION AND DISEASE PREVALENCE ARE DRIVING MARKET GROWTH
             10.5.2 COVID-19 IMPACT ON THE LATAM MARKET
           TABLE 188 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 189 LATIN AMERICA: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 190 LATIN AMERICA: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 191 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION)
           TABLE 192 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
     10.6 MIDDLE EAST AND AFRICA
             10.6.1 UNSATURATED MARKETS IN THE REGION HAVE DRAWN THE ATTENTION OF GLOBAL PLAYERS
             10.6.2 COVID-19 IMPACT ON THE MEA MARKET
           TABLE 193 MIDDLE EAST AND AFRICA: PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 194 MIDDLE EAST AND AFRICA: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 195 MIDDLE EAST AND AFRICA: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 196 MIDDLE EAST AND AFRICA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION)
           TABLE 197 MIDDLE EAST AND AFRICA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 218)
     11.1 INTRODUCTION
           FIGURE 33 KEY PLAYER STRATEGIES
     11.2 COMPANY GEOGRAPHIC FOOTPRINT: PHARMACEUTICAL EXCIPIENTS MARKET
           FIGURE 34 COMPANY GEOGRAPHIC FOOTPRINT: PHARMACEUTICAL EXCIPIENTS MARKET (2020)
     11.3 COMPETITIVE LEADERSHIP MAPPING
             11.3.1 STARS
             11.3.2 EMERGING LEADERS
             11.3.3 PERVASIVE PLAYERS
             11.3.4 PARTICIPANTS
           FIGURE 35 PHARMACEUTICAL EXCIPIENTS MARKET: COMPETITIVE LEADERSHIP MAPPING (2019)
     11.4 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2020)
             11.4.1 PROGRESSIVE COMPANIES
             11.4.2 DYNAMIC COMPANIES
             11.4.3 STARTING BLOCKS
             11.4.4 RESPONSIVE COMPANIES
           FIGURE 36 PHARMACEUTICAL EXCIPIENTS MARKET: START-UP COMPANY EVALUATION MATRIX (2020)
     11.5 MARKET SHARE ANALYSIS
           FIGURE 37 PHARMACEUTICAL EXCIPIENTS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
     11.6 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
           FIGURE 38 REVENUE ANALYSIS OF THE TOP PLAYERS IN THE PHARMACEUTICAL EXCIPIENTS MARKET
     11.7 PRODUCT FOOTPRINT
     11.8 COMPETITIVE SITUATIONS AND TRENDS
           TABLE 198 PRODUCT LAUNCHES (2017-2020)
           TABLE 199 MERGERS & ACQUISITIONS (2017-2020)
           TABLE 200 AGREEMENTS & PARTNERSHIPS (2017-2020)
           TABLE 201 EXPANSIONS (2017-2020)
           TABLE 202 OTHER DEVELOPMENTS (2017-2020)

12 COMPANY PROFILES (Page No. - 231)
     12.1 KEY PLAYERS
             12.1.1 DUPONT DE NEMOURS, INC.
           TABLE 203 DUPONT DE NEMOURS: BUSINESS OVERVIEW
           FIGURE 39 DUPONT DE NEMOURS, INC.: COMPANY SNAPSHOT (2019)
             12.1.2 ROQUETTE FRΘRES
           TABLE 204 ROQUETTE FRΘRES: BUSINESS OVERVIEW
             12.1.3 ASHLAND
           TABLE 205 ASHLAND: BUSINESS OVERVIEW
           FIGURE 40 ASHLAND: COMPANY SNAPSHOT (2020)
             12.1.4 EVONIK INDUSTRIES AG
           TABLE 206 EVONIK INDUSTRIES: BUSINESS OVERVIEW
           FIGURE 41 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2019)
             12.1.5 BASF SE
           TABLE 207 BASF SE: BUSINESS OVERVIEW
           FIGURE 42 BASF SE: COMPANY SNAPSHOT (2019)
             12.1.6 KERRY GROUP PLC
           TABLE 208 KERRY GROUP: BUSINESS OVERVIEW
           FIGURE 43 KERRY GROUP PLC: COMPANY SNAPSHOT (2019)
     12.2 OTHER PLAYERS
             12.2.1 CRODA INTERNATIONAL
           TABLE 209 CRODA INTERNATIONAL: BUSINESS OVERVIEW
           FIGURE 44 CRODA INTERNATIONAL: COMPANY SNAPSHOT (2019)
             12.2.2 ASSOCIATED BRITISH FOODS PLC
           TABLE 210 ASSOCIATED BRITISH FOODS PLC: BUSINESS OVERVIEW
           FIGURE 45 ASSOCIATED BRITISH FOODS PLC: COMPANY SNAPSHOT (2020)
             12.2.3 ARCHER DANIELS MIDLAND COMPANY
           TABLE 211 ARCHER DANIELS MIDLAND: BUSINESS OVERVIEW
           FIGURE 46 ARCHER DANIELS MIDLAND COMPANY: COMPANY SNAPSHOT (2019)
             12.2.4 LUBRIZOL CORPORATION
           TABLE 212 LUBRIZOL CORPORATION: BUSINESS OVERVIEW
             12.2.5 INNOPHOS HOLDINGS, INC.
           TABLE 213 INNOPHOS HOLDINGS: BUSINESS OVERVIEW
           FIGURE 47 INNOPHOS HOLDINGS, INC.: COMPANY SNAPSHOT (2019)
             12.2.6 WACKER CHEMIE AG
           TABLE 214 WACKER CHEMIE AG: BUSINESS OVERVIEW
           FIGURE 48 WACKER CHEMIE AG: COMPANY SNAPSHOT (2019)
             12.2.7 AIR LIQUIDE S.A.
           TABLE 215 AIR LIQUIDE: BUSINESS OVERVIEW
           FIGURE 49 AIR LIQUIDE S.A.: COMPANY SNAPSHOT (2019)
             12.2.8 COLORCON, INC.
           TABLE 216 COLORCON, INC.: BUSINESS OVERVIEW
             12.2.9 DMV-FONTERRA EXCIPIENTS GMBH & CO. KG
           TABLE 217 DMV-FONTERRA EXCIPIENTS GMBH & CO. KG.: BUSINESS OVERVIEW
             12.2.10 JRS PHARMA GMBH & CO. KG
           TABLE 218 JRS PHARMA GMBH & CO. KG.: BUSINESS OVERVIEW
             12.2.11 MERCK KGAA
           TABLE 219 MERCK KGAA.: BUSINESS OVERVIEW
           FIGURE 50 MERCK KGAA: COMPANY SNAPSHOT (2019)
             12.2.12 DOW CHEMICALS
           TABLE 220 DOW CHEMICALS: BUSINESS OVERVIEW
           FIGURE 51 DOW CHEMICALS: COMPANY SNAPSHOT (2019)
             12.2.13 FINAR LIMITED
             12.2.14 MEGGLE EXCIPIENTS & TECHNOLOGY

13 APPENDIX (Page No. - 296)
     13.1 INDUSTRY SPEAKS
     13.2 DISCUSSION GUIDE
     13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.4 AUTHOR DETAILS

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the use of comprehensive secondary sources; directories and databases such as D&B, Bloomberg Business, and Factiva; and white papers, annual reports, and company house documents. Secondary research was used to identify and collect information for this extensive, technical, market-oriented, and commercial study of the global pharmaceutical excipients market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, technology perspectives, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the pharmaceutical excipients market. The primary sources from the demand side include industry experts such as experts from drugs manufacturing companies, nutraceutical companies, and contract manufacturing organizations.

A breakdown of the primary respondents is provided below:

Pharmaceutical Excipients Market   Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by polymer type, functionality, type, end user, and region).

Data Triangulation

After arriving at the market size, the total pharmaceutical excipients market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, data triangulation, and market breakdown procedures were employed, wherever applicable.

Objectives of the Study

  • To define, describe, segment, and forecast the pharmaceutical excipients market by Product, functionality, formulation, and region
  • To provide detailed information about the factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall pharmaceutical excipients market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the pharmaceutical excipients market in five main regions (along with their respective key countries), namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the pharmaceutical excipients market and comprehensively analyze their core competencies and market shares
  • To track and analyze competitive developments such as acquisitions; new product launches; expansions; collaborations, agreements, and partnerships; and R&D activities of the leading players in the pharmaceutical excipients market
  • To benchmark players within the pharmaceutical excipients market using the "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)

Geographic Analysis

  • Further breakdown of the Rest of Asia Pacific pharmaceutical excipients market into Singapore, New Zealand, and others
  • Further breakdown of the Rest of Europe pharmaceutical excipients market into the Belgium, Netherlands, Denmark, and others
COVID-19

Get in-depth analysis of the COVID-19 impact on the Pharmaceutical Excipients Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Pharmaceutical Excipients Market

Request For Special Pricing
Report Code
PH 3047
Published ON
Mar, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Pharmaceutical Excipients Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home